Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection

References

• Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Nat Microbiol. Nat Microbiol. 2020;5:536–544.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al., A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269.
   PubMed Web of Science ®Google Scholar
• Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207.
   Web of Science ®Google Scholar
• Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoVinfection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–971.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Bhattacharya M, et al. The 2019 novel coronavirus disease (COVID-19) pandemic: A zoonotic prospective. Asian Pac J Trop Med. 2020;13(6):242.
   Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. bioRxiv. 2020:2020.01.24.919183. doi:10.1101/2020.01.24.919183.
   Google Scholar
• Hoffmann M, Kleine-Weber H, Krüger N, et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020. DOI:10.1101/2020.01.31.929042. 2020.01.31.929042.
   Google Scholar
• Jiang S, ME B, Du L, et al., Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012;11(12):1405–1413.
   PubMed Web of Science ®Google Scholar
• Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–432.
   PubMed Web of Science ®Google Scholar
• Sambhara S, McElhaney JE. Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol. 2009;333:413–429.
   PubMedGoogle Scholar
• Chen WH, Strych U, Hotez PJ, et al. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep. 2020;1–4.
   PubMedGoogle Scholar
• Karch CP, Burkhard P. Vaccine technologies: from whole organisms to rationally designed protein assemblies. Biochem Pharmacol. 2016;120:1–14.
   PubMed Web of Science ®Google Scholar
• Vivona S, Gardy JL, Ramachandran S, et al. Computer-aided biotechnology: from immuno-informatics to reverse vaccinology. Trends Biotechnol. 2008;26(4):190–200.
   PubMed Web of Science ®Google Scholar
• Liu Z, Xiao Y, Chen YH. Epitope-vaccine Strategy against HIV-1: today and Tomorrow. Immunobiology. 2003;208(4):423–428.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Pilati P, Nitti D. Peptide-based anticancer vaccines: recent advances and future perspectives. Curr Med Chem. 2009;16(36):4779–4796.
   PubMed Web of Science ®Google Scholar
• Lazoura E, Lodding J, Farrugia W, et al. Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide. Immunology. 2006;119(3):306–316.
   PubMed Web of Science ®Google Scholar
• Pietersz GA, Pouniotis DS, Apostolopoulos V. Design of peptide-based vaccines for cancer. Curr Med Chem. 2006;13(14):1591–1607.
   PubMed Web of Science ®Google Scholar
• Ali FR, Larche M. Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Rev Vaccines. 2005;4(6):881–889.
   PubMed Web of Science ®Google Scholar
• Structure LF. Function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3(1):237–261.
   PubMedGoogle Scholar
• Chakraborty C, Sharma AR, Sharma G, et al. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci. 2020;24(7):4016–4026.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al., Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263.
   PubMed Web of Science ®Google Scholar
• He Y, Li J, Li W, et al. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol. 2006;176(10):6085–6092.
   PubMed Web of Science ®Google Scholar
• He Y, Jiang S. Vaccine design for severe acute respiratory syndrome coronavirus. Viral Immunol. 2005;18(2):327–332.
   PubMed Web of Science ®Google Scholar
• Jiang S, He Y, Liu S. SARS vaccine development. Emerg Infect Dis. 2005;11(7):1016–1020.
   PubMed Web of Science ®Google Scholar
• Marra MA, Jones SJ, Astell CR, et al. The genome sequence of the SARS-associated coronavirus. Science. 2003;300(5624):1399–1404.
   PubMed Web of Science ®Google Scholar
• Chang CK, Hou MH, Chang CF, et al. The SARS coronavirus nucleocapsid protein – forms and functions. Antiviral Res. 2014;(2014(103):39–50.
   Google Scholar
• Wei WY, Li HC, Chen CY, et al. SARS-CoV nucleocapsid protein interacts with cellular pyruvate kinase protein and inhibits its activity. Arch Virol. 2012;157(4):635–645.
   PubMed Web of Science ®Google Scholar
• Jimenez-Guardeno JM, Nieto-Torres JL, DeDiego ML, et al. The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis. PLoS Pathog. 2014;10(8):e1004320.
   PubMed Web of Science ®Google Scholar
• Bhattacharya M, Sharma AR, Patra P, et al. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach. J Med Virol. 2020;92(6):618–631.
   PubMed Web of Science ®Google Scholar
• Kumar S. Drug and vaccine design against Novel Coronavirus (2019-nCoV) spike protein through Computational approach. 2020. Preprints 2020, 2020020071. DOI: 10.20944/preprints202002.0071.v1
   Google Scholar
• Feng Y, Qiu M, Zou S, et al. Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus in China (SARS-CoV-2). bioRxiv. 2020. DOI:10.1101/2020.03.03.962332
   Google Scholar
• Enayatkhani M, Hasaniazad M, Faezi S, et al. Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study. J Biomol Struct Dyn. 2020:1–19. doi:10.1080/07391102.2020.1756411.
   PubMed Web of Science ®Google Scholar
• Saha S, Raghava GPS. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins. 2006;65(1):40–48.
   PubMed Web of Science ®Google Scholar
• Reynisson B, Alvarez B, Paul S, et al. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1):W449-W454.
   PubMed Web of Science ®Google Scholar
• Larsen MV, Lundegaard C, Lamberth K, et al. Large-scale validation of methods for cytotoxic Tlymphocyte epitope prediction. BMC Bioinformatics. 2007;8(1):424.
   PubMed Web of Science ®Google Scholar
• Fleri W, Paul S, Dhanda SK, et al. The immune epitope database and analysis resource in epitope discovery and synthetic vaccine design. Front Immunol. 2017;8:278.
   PubMed Web of Science ®Google Scholar
• Gupta S, Kapoor P, Chaudhary K, et al. In silico approach for predicting toxicity of peptides and proteins. PLoS One. 2013;8(9):e73957.
   PubMed Web of Science ®Google Scholar
• Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007;8(1):4.
   PubMed Web of Science ®Google Scholar
• Tomar N, De RK. Immunoinformatics: an integrated scenario. Immunology. 2010;131(2):153–168.
   PubMed Web of Science ®Google Scholar
• Dimitrov I, Bangov I, Flower DR, et al. AllerTOP v.2–a server for in silico prediction of allergens. J Mol Model. 2014;20(6):2278.
   PubMed Web of Science ®Google Scholar
• Tani K, Murphy WJ, Chertov O. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int Immunol. 2000;12(5):691–700.
   PubMed Web of Science ®Google Scholar
• Foged C. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther Deliv. 2011;2(8):1057–1077.
   PubMedGoogle Scholar
• Pandey RK, Ojha R, Aathmanathan VS, et al. Immunoinformatics approaches to design a novel multi-epitope subunit vaccine against HIV infection. Vaccine. 2018;36(17):2262–2272.
   PubMed Web of Science ®Google Scholar
• H H B, Sidney J, Dinh K, et al. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics. 2006;7:153.
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Gasteiger E, Bairoch A, et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol. 1999;112:531–552.
   PubMedGoogle Scholar
• Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res. 2004;32:W526–531.
   PubMed Web of Science ®Google Scholar
• Laskowski RA, MacArthur MW, Moss DS, et al. PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26(2):283–291.
   Web of Science ®Google Scholar
• Eisenberg D, Luthy R, Bowie JU. Verify 3D: assessment of protein models with three dimensional profiles. Methods Enzymol. 1997;277:396–404.
   PubMed Web of Science ®Google Scholar
• Colovos C, Yeates TO. Verification of protein structure: patterns of non-bonded atomic interaction. Protein Sci. 1993;2(9):1511–1519.
   PubMed Web of Science ®Google Scholar
• Kozakov D, Hall DR, Xia B, et al. The ClusPro web server for protein-protein docking. Nat Protoc. 2017;12(2):255–278.
   PubMed Web of Science ®Google Scholar
• Lindahl E, Hess B, Van Der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. Mol Model Ann. 2001;7:306–317.
   Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graphics. 1996;14(1):33–38.
   PubMedGoogle Scholar
• Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020;41(5):355–359.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang Y, Huang J, et al. Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain. Viruses. 2019;11(1):60.
   PubMed Web of Science ®Google Scholar
• Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236.
   PubMed Web of Science ®Google Scholar
• Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect. 2020;9(1):275–277.
   PubMed Web of Science ®Google Scholar
• Oppenheim JJ, Biragyn A, Kwak LW, et al. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis. 2003;62(90002):17–21.
   Google Scholar
• Soria-Guerra RE, Nieto-Gomez R, Govea-Alonso DO, et al. An overview of bioinformatics tools for epitope prediction: implications on vaccine development. J Biomed Inform. 2015;53:405–414.
   PubMed Web of Science ®Google Scholar
• Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics. 1999;50(3–4):201–212.
   PubMed Web of Science ®Google Scholar
• Totura AL, Whitmore A, Agnihothram S, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio. 2015;6(3):e00638–15.
   PubMed Web of Science ®Google Scholar
• Saha A, Sharma AR, Bhattacharya M, et al. Probable molecular mechanism of remdesivir for the treatment of COVID-19: need to know more. Arch Med Res. 2020. DOI:10.1016/j.arcmed.2020.05.001.
   Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Bhattacharya M, et al. Consider TLR5 for new therapeutic development against COVID‐19. J Med Virol. 2020. DOI:10.1002/jmv.25997.
   Web of Science ®Google Scholar
• Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52(4):583–589.
   PubMed Web of Science ®Google Scholar
• Janice Oh HL, Ken-En Gan S, Bertoletti A, et al. Understanding the T cell immune response in SARS coronavirus infection. Emerg Microbes Infect. 2012;1(9):e23.
   PubMedGoogle Scholar
• Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD41 T cells are important in control of SARS-CoV infection. J Virol. 2010;84(3):1289–1301.
   PubMed Web of Science ®Google Scholar
• Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84(18):9318–9325.
   PubMed Web of Science ®Google Scholar
• Zhao J, Van Rooijen N, Perlman S. Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice. PLoS Pathog. 2009;5:e1000636.
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Huang LM, Chen PJ, et al. Chronological evolution of IgM,IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004;10(12):1062–1066.
   PubMed Web of Science ®Google Scholar
• Buchholz UJ, Bukreyev A, Yang L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA. 2004;101(26):9804–9809.
   PubMed Web of Science ®Google Scholar
• Wang YD, Sin WY, Xu GB, et al. T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J Virol. 2004;78(11):5612–5618.
   PubMed Web of Science ®Google Scholar
• Peng H, Yang LT, Wang LY, et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology. 2006;351(2):466–475.
   PubMed Web of Science ®Google Scholar
• Leung DT, Tam FC, Ma CH, et al. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J Infect Dis. 2004;190(2):379–386.
   PubMed Web of Science ®Google Scholar
• Li CK, Wu H, Yan H, et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008;181(8):5490–5500.
   PubMed Web of Science ®Google Scholar
• Jin H, Xiao C, Chen Z, et al. Induction of Th1 type response by DNA vaccinations with N,M, and E genes against SARS-CoV in mice. Biochem Biophys Res Commun. 2005;328(4):979–986.
   PubMed Web of Science ®Google Scholar
• Yang L, Peng H, Zhu Z, et al. Persistent memory CD41 and CD81 T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen. J Gen Virol. 2007;88(10):2740–2748.
   PubMedGoogle Scholar